AffyXell snags $7.3m Series A

AffyXell Therapeutics, a developer of novel mesenchymal stem cell therapies, has raised $7.3 million in Series A funding.

AffyXell Therapeutics, a developer of novel mesenchymal stem cell therapies, has raised $7.3 million in Series A funding. The investors include Samsung Venture Investment Corporation, Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corporation, Kolon Investment, Stonebridge Ventures, and Gyeongnam Venture Investment.

Source: Press Release